Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of ERAS is 20 and suggests 42% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase